Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation Study of Bosutinib in ALS
jRCT2051190001Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bosutinib in amyotrophic lateral sclerosis (ALS), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Dose-limiting toxicity (DLT). Started Mar 2019; status: recruiting.
02
Drugs
bosutinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2051190001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190001.